Welcome to our dedicated page for Innate Pharma Marseille SEC filings (Ticker: IPHYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innate Pharma S.A. (IPHYF) SEC Filings provides access to the company’s regulatory disclosures as a foreign private issuer. Innate Pharma S.A. reports to the U.S. Securities and Exchange Commission using Form 20-F and submits Form 6-K current reports that often include press releases as exhibits, such as those dated in September 2025.
On this page, you can review Innate Pharma S.A.’s 6-K and related filings as they are made available through the SEC’s EDGAR system. These documents include current reports that reference press releases, along with detailed financial and structural information prepared under IFRS, covering items such as ordinary and preference shares, issued capital, share premium, retained earnings, accumulated other comprehensive income, and various categories of shareholders.
Filings also describe assets and financing arrangements, including licences, intangible assets under development, land and buildings, laboratory equipment, construction in progress, and right-of-use assets. The disclosures reference loan agreements and lease financing obligations, such as a PGELoanAgreement with Societe Generale and BNP Paribas, and lease obligations for buildings, premises, equipment, vehicles, printers, and other assets.
Stock Titan enhances these filings with AI-powered summaries that help explain the structure and content of lengthy regulatory documents. Users can quickly identify key sections in Innate Pharma S.A.’s 6-K and other filings, see how capital structure and financing are presented, and locate information related to shareholders and counterparties, all without reading every line of the original text.
Innate Pharma S.A. reported a 2025 net loss of €49.2 million, broadly in line with 2024, as revenue and other income fell 55% to €9.0 million mainly due to lower collaboration and licensing revenue from AstraZeneca and Sanofi.
Cash, cash equivalents, short-term investments and financial assets totaled €44.8 million as of December 31, 2025, giving an estimated cash runway only until the end of Q3 2026. Shareholders’ equity turned negative at €(21.7) million, and the company states there is substantial doubt about its ability to continue as a going concern while it pursues non-dilutive financing options.
R&D expenses declined 16% to €43.6 million as the pipeline was strategically refocused, including discontinuation of IPH6501, while key programs such as lacutamab, IPH4502 and partnered assets with AstraZeneca and Sanofi continue to advance toward significant data and regulatory milestones in 2026.
Innate Pharma S.A. filed a Form 6-K to share details of an upcoming conference call and webcast for its full year 2025 financial results. The call will take place on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of results for the year ended December 31, 2025.
Senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Chief Financial Officer and Vice President of Investor Relations, will participate. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.
Innate Pharma SA ownership update: Novo Nordisk A/S reports beneficial ownership of 7,333,778 ordinary shares, representing 7.82% of the class as of 12/31/2025. The filing shows sole voting and dispositive power over 7,333,778 shares.
The form is an amended Schedule 13G/A filed and signed on 03/04/2026 by Karsten Munk Knudsen, Chief Financial Officer.
Innate Pharma S.A. filed a report noting that its executive team will take part in the Leerink Partners Global Healthcare Conference 2026 in Miami from March 8–11. The company will host a fireside chat on March 9 at 3:40 PM ET, with a live webcast and replay available through the Investors section of its website.
The filing also highlights Innate Pharma’s focus on developing next-generation antibody-based immunotherapies for cancer, including IPH4502, lacutamab and monalizumab, and mentions ongoing collaborations with major partners such as AstraZeneca and Sanofi.
Innate Pharma S.A. furnished a Form 6-K as a foreign private issuer, providing its H1 2025 Half-Year Financial Report for the period from January 1 to June 30, 2025. The half-year report is attached as Exhibit 99.2 and contains the company’s detailed financial and operating information.
The company states that this Form 6-K and Exhibit 99.2 (excluding the statutory auditors' review report on page 49) are incorporated by reference into its existing registration statements on Form F-3 and Form S-8, meaning the half-year information becomes part of those U.S. securities offering documents.